Trial Profile
A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Venetoclax (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms DEC10-VEN
- 03 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2023 Results assessing transcriptomic and DNA methylation analyses on VEN/DEC pre- and post-treatment samples from AML patients participating in a prospective clinical trial of DEC10-VEN (NCT03404193), were assessing presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results (n=33) single-cell proteogenomics analysis on samples from AML patients treated with decitabine+venetoclax presented at the 65th American Society of Hematology Annual Meeting and Exposition